Stem Cell Treatments

TRANSVERSE MYELITIS

Transverse myeltis is a condition that results in the inflammation of the myelin sheath of the spinal cord. The area targeted goes across the width of the spinal cord at a certain level of the spinal cord. The problem occurs after vaccines (DPT, Influenza etc. , viral infections, post radiation treatments. The underlying problem is that certain elements of the patient’s own immune system cause inflammation and sometimes destruction of the myelin.
Symptoms include pain in the arms, legs, back and neck; numbness, paresthesias, numbness below the affected area of the spinal cord; weakness of the arms and legs; muscle spasms; headache.
Tests may include lumbar spinal tap; functional MRI; NMO-IgG test.
Many patients will clear up uneventfully after the acute phase; others may have relapses; some patients may go into a chronic phase with partial or total paralysis of the upper and lower extremities; spasticity; osteoporosis and sexual dysfunction.
Treatment initially should include intravenous cortisone. If symptoms continue plasma exchange therapy (apheresis) is considered. If the condition does not improve StemCellRegenMed recommends the following:

Autologous stem cells. The patient is given an injection of G-CSF once daily for three days. Peripheral blood or a bone marrow aspirate is withdrawn and in the laboratory autologous stem cells are extracted and administered to the patient.
Following this the patient is given by spinal canal administration at the level of disease neuron stem cells mixed with neurotrophins, nerve cell factor, neuropeptide protein, glial derived neurotrophins oligodendrocytes. In addition the following may be given riluzole that targets sodium dysregulation in the affected spinal cord; minocycline that targets apoptosis and neuroinflammation.
Targeting immune factors include anti-IL-6; anti-TNF; IL-17 and IL-1beta which attack the myelin in this condition.
Targeting axonal inhibitors such as Rho with Cethrin and ATI-355 against Nogo.
Electric field stimulation.

.
Medical Disclaimer: Treatments discussed on this website are experimental and have not been approved by the FDA. No guarantees are made regarding the results of these treatments. Prospective patients are advised to discuss the use of a Stem Cell treatment for their disease with their physician.


		TRANSVERSE MYELITIS Transverse myeltis is a condition that results in the inflammation of the myelin sheath of the spinal cord. The area targeted goes across the width of the spinal cord at a certain level of the spinal cord. The problem occurs after vaccines (DPT, Influenza etc. , viral infections, post radiation treatments. The underlying problem is that certain elements of the patient’s own immune system cause inflammation and sometimes destruction of the myelin. Symptoms include pain in the arms, legs, back and neck; numbness, paresthesias, numbness below the affected area of the spinal cord; weakness of the arms and legs; muscle spasms; headache. Tests may include lumbar spinal tap; functional MRI; NMO-IgG test. Many patients will clear up uneventfully after the acute phase; others may have relapses; some patients may go into a chronic phase with partial or total paralysis of the upper and lower extremities; spasticity; osteoporosis and sexual dysfunction. Treatment initially should include intravenous cortisone. If symptoms continue plasma exchange therapy (apheresis) is considered. If the condition does not improve StemCellRegenMed recommends the following: Autologous stem cells. The patient is given an injection of G-CSF once daily for three days. Peripheral blood or a bone marrow aspirate is withdrawn and in the laboratory autologous stem cells are extracted and administered to the patient. Following this the patient is given by spinal canal administration at the level of disease neuron stem cells mixed with neurotrophins, nerve cell factor, neuropeptide protein, glial derived neurotrophins oligodendrocytes. In addition the following may be given riluzole that targets sodium dysregulation in the affected spinal cord; minocycline that targets apoptosis and neuroinflammation. Targeting immune factors include anti-IL-6; anti-TNF; IL-17 and IL-1beta which attack the myelin in this condition. Targeting axonal inhibitors such as Rho with Cethrin and ATI-355 against Nogo. Electric field stimulation. . Medical Disclaimer: Treatments discussed on this website are experimental and have not been approved by the FDA. No guarantees are made regarding the results of these treatments. Prospective patients are advised to discuss the use of a Stem Cell treatment for their disease with their physician.